These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15983920)

  • 1. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1.
    de Mendoza C; Rodriguez C; Eiros JM; Colomina J; Garcia F; Leiva P; Torre-Cisneros J; Aguero J; Pedreira J; Viciana I; Corral A; del Romero J; Ortiz de Lejarazu R; Soriano V
    Clin Infect Dis; 2005 Jul; 41(2):227-32. PubMed ID: 15983920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance.
    de Mendoza C; Rodriguez C; García F; Eiros JM; Ruíz L; Caballero E; Aguilera A; Leiva P; Colomina J; Gutierrez F; del Romero J; Aguero J; Soriano V;
    J Antimicrob Chemother; 2007 Apr; 59(4):698-704. PubMed ID: 17327295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
    de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
    J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
    Prado JG; Parkin NT; Clotet B; Ruiz L; Martinez-Picado J
    Clin Infect Dis; 2005 Sep; 41(5):729-37. PubMed ID: 16080097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
    Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
    J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
    Campbell TB; Shulman NS; Johnson SC; Zolopa AR; Young RK; Bushman L; Fletcher CV; Lanier ER; Merigan TC; Kuritzkes DR
    Clin Infect Dis; 2005 Jul; 41(2):236-42. PubMed ID: 15983922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication. Antiretroviral drug resistance among drug-naive HIV-1-infected individuals in Djibouti (Horn of Africa).
    Maslin J; Rogier C; Caron M; Grandadam M; Koeck JL; Nicand E
    Antivir Ther; 2005; 10(7):855-9. PubMed ID: 16312182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.
    Hatano H; Hunt P; Weidler J; Coakley E; Hoh R; Liegler T; Martin JN; Deeks SG
    Clin Infect Dis; 2006 Nov; 43(10):1329-36. PubMed ID: 17051502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
    Benson CA; Vaida F; Havlir DV; Downey GF; Lederman MM; Gulick RM; Glesby MJ; Wantman M; Bixby CJ; Rinehart AR; Snyder S; Wang R; Patel S; Mellors JW;
    J Infect Dis; 2006 Nov; 194(9):1309-18. PubMed ID: 17041858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population.
    Leigh Brown AJ; Frost SD; Mathews WC; Dawson K; Hellmann NS; Daar ES; Richman DD; Little SJ
    J Infect Dis; 2003 Feb; 187(4):683-6. PubMed ID: 12599087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worldwide transmission of drug-resistant HIV.
    Wensing AM; Boucher CA
    AIDS Rev; 2003; 5(3):140-55. PubMed ID: 14598563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
    Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
    Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy.
    Murray JM
    J Infect Dis; 2003 Oct; 188(8):1258; author reply 1258-9. PubMed ID: 14551898
    [No Abstract]   [Full Text] [Related]  

  • 20. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.